Susan Bernstein | Issue: March 2020 |
Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…
Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.